Ulcerative keratitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 05 Jun 2026 10:50:49 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Ulcerative keratitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Allogenic Stem Cells and Amniotic Membrane for Patients with Advanced Corneal Ulcers Unresponsive to Standard Treatment https://clinicaltrials.eu/trial/study-on-allogenic-stem-cells-and-amniotic-membrane-for-patients-with-advanced-corneal-ulcers-unresponsive-to-standard-treatment/ Wed, 29 Apr 2026 14:27:41 +0000 https://clinicaltrials.eu/trial/study-on-allogenic-stem-cells-and-amniotic-membrane-for-patients-with-advanced-corneal-ulcers-unresponsive-to-standard-treatment/ This clinical trial is focused on studying a severe eye condition known as corneal trophic ulcers. These ulcers are advanced and do not respond to standard eye treatments. The study aims to evaluate a new treatment using a special type of artificial cornea, called a nanostructured artificial human cornea. This treatment involves using a combination of human tissues, including the amniotic membrane and allogenic sclerocorneal limbus stem-derived adult limbal cells, which are cells taken from the eye’s surface and expanded outside the body. The treatment is designed to help patients who have no other effective options for their severe corneal disease.

The purpose of the study is to assess the safety and practicality of this new treatment approach. Participants in the study will receive the treatment through a process called implantation, where the artificial cornea is placed onto the eye. The study will monitor the condition of the graft, which is the implanted cornea, to ensure it remains intact and does not cause any adverse effects. Researchers will also look for any signs of infection or unwanted blood vessel growth in the eye.

Throughout the study, the health of the participants’ eyes will be closely observed. This includes checking for improvements in visual acuity, which is the clarity of vision, and corneal transparency, which refers to how clear the cornea is. The study will also assess the overall quality of life of the participants and use techniques like impression cytology and OCT mapping to examine the surface of the cornea. The trial is expected to continue until 2027, providing valuable insights into the potential of this innovative treatment for those suffering from severe corneal conditions.

]]> Study on the Effectiveness of NANOULCOR for Patients with Severe Corneal Ulcers Using Allogenic Limbal Cells and Keratocytes https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-nanoulcor-for-patients-with-severe-corneal-ulcers-using-allogenic-limbal-cells-and-keratocytes/ Wed, 29 Apr 2026 14:26:11 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-nanoulcor-for-patients-with-severe-corneal-ulcers-using-allogenic-limbal-cells-and-keratocytes/ This clinical trial is focused on studying a condition known as corneal ulcer, which is a painful open sore on the clear front surface of the eye. The trial is testing a new treatment called NANOULCOR, which is an artificial cornea made from a special combination of cells. These cells include allogenic sclerocorneal limbus stem-derived adult limbal cells and allogenic corneal-derived adult keratocytes, both of which are expanded outside the body and then combined in a biological matrix to form a living tissue equivalent. This treatment is designed to help patients with severe corneal ulcers that do not respond to standard therapies.

The purpose of the study is to evaluate how well NANOULCOR works in healing the corneal ulcers compared to a control group. Participants in the study will receive the treatment through implantation, and the study will monitor the healing process of the corneal ulcers over time. The trial will also look at other factors such as changes in vision, any complications that may arise, and the overall quality of life of the participants. The study will record any side effects and assess the condition of the implanted corneal construct to ensure it remains intact and does not detach or dissolve.

This trial is a Phase IIb study, which means it is in the middle stages of testing the treatment’s effectiveness and safety. It is a randomized, controlled, and unblinded study, meaning participants will be randomly assigned to receive either the new treatment or a control, and both the researchers and participants will know which treatment is being administered. The study is being conducted at multiple centers and aims to provide valuable information on the potential benefits of NANOULCOR for patients with severe corneal ulcers.

]]>